This segment focuses on the research, development, and clinical evaluation of oral small molecule therapeutics for immunological diseases. DICE Therapeutics utilizes its proprietary DELSCAPE platform to identify and develop drug candidates that modulate protein-protein interactions (PPIs) with the goal of achieving the efficacy of biologics through oral administration. The lead candidate, S011806, is an oral antagonist of interleukin-17 (IL-17), a key pro-inflammatory cytokine implicated in various autoimmune and inflammatory conditions like psoriasis. Research and development activities include preclinical studies, Phase 1 and Phase 2 clinical trials, and formulation development. The company aims to improve patient outcomes by providing convenient and effective oral treatments, potentially reducing the need for injectable biologics. Market positioning is centered on providing innovative oral therapies in a competitive market. Future opportunities include expanding the pipeline to address other immunology indications and advancing clinical trials to later stages. Regulatory and clinical aspects involve obtaining FDA approval and demonstrating safety and efficacy in clinical trials. This segment is now part of Eli Lilly and Company after the acquisition.

This segment encompasses the core technology platform, DELSCAPE, which is used to discover and develop novel oral small molecule drugs. The DELSCAPE platform is designed to identify small molecules that can effectively modulate protein-protein interactions (PPIs), a key mechanism in many disease pathways. Research and development activities include high-throughput screening, medicinal chemistry, and computational biology to identify and optimize drug candidates. The platform's technology allows for the identification of selective oral small molecules that can modulate PPIs as effectively as systemic biologics. This segment focuses on the discovery of new drug candidates and the expansion of the pipeline. The platform's competitive advantage lies in its ability to identify and develop oral drugs, which can offer advantages in terms of patient convenience and compliance. Future opportunities include expanding the platform to target other therapeutic areas and partnering with other pharmaceutical companies. Regulatory and clinical aspects involve the development of intellectual property and the protection of trade secrets. This segment is now part of Eli Lilly and Company after the acquisition.